Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis

Background: Renal involvement is common in systemic lupus erythematosus (SLE) and can lead to chronic kidney disease (CKD). Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. Due to its invasiveness, repeat renal biopsy for monitoring disease activity is not recommended, thus creating a...

Full description

Saved in:
Bibliographic Details
Main Author: Rusch, Jody Alan
Other Authors: Okpechi, Ikechi Gareth
Format: Thesis
Language:English
Published: Division of Chemical Pathology 2021
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613239769038848
access_status_str Open Access
author Rusch, Jody Alan
author2 Okpechi, Ikechi Gareth
author_browse Okpechi, Ikechi Gareth
Rusch, Jody Alan
author_facet Okpechi, Ikechi Gareth
Rusch, Jody Alan
author_sort Rusch, Jody Alan
collection Thesis
description Background: Renal involvement is common in systemic lupus erythematosus (SLE) and can lead to chronic kidney disease (CKD). Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. Due to its invasiveness, repeat renal biopsy for monitoring disease activity is not recommended, thus creating a need for noninvasive and accurate biomarkers. Monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-like weak inducer of apoptosis (TWEAK) have been implicated in the pathogenesis of LN and are thus potential biomarkers for disease activity monitoring. Methods: In this study urinary MCP-1 (uMCP-1) and TWEAK (uTWEAK), together with standard markers of disease activity, were analysed in a cohort of 50 biopsy-proven LN patients at baseline, after sixmonths of induction therapy, and at one-year. Results: Throughout the study there was correlation between uMCP-1 and uTWEAK (r=0.52, p< 0.001). Both biomarkers also correlated with standard of care tests and clinical scores. The median [interquartile range] of uMCP-1 and uTWEAK were significantly increased in the active group when compared to the quiescent group (1440 [683–2729] vs 256 [175–477] pg/mL, p< 0.0001, and 209 [117–312] vs 74 [11– 173] pg/mL, p=0.0008, respectively). After completion of induction therapy in the active group, there was no significant difference in biomarker results between the groups. The sensitivity and specificity for indicating disease activity was 95% and 73% for uMCP-1 (area under curve [AUC]=0.875), and 60% and 90% for uTWEAK (AUC=0.783), respectively. Conclusion: uMCP-1 and uTWEAK reflect LN disease activity, and correlate with standard of care biomarkers in a South African cohort. Further studies are needed to assess additional clinical benefit.
format Thesis
id oai:open.uct.ac.za:11427/33899
institution University of Cape Town (South Africa)
language eng
last_indexed 2026-06-10T12:32:58.612Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher Division of Chemical Pathology
publisherStr Division of Chemical Pathology
record_format dspace
source_str UCTD — University of Cape Town Open Access Repository
spelling oai:open.uct.ac.za:11427/33899 Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis Rusch, Jody Alan Okpechi, Ikechi Gareth Omar, Fierdoz Chemical Pathology Nephrology Background: Renal involvement is common in systemic lupus erythematosus (SLE) and can lead to chronic kidney disease (CKD). Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. Due to its invasiveness, repeat renal biopsy for monitoring disease activity is not recommended, thus creating a need for noninvasive and accurate biomarkers. Monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-like weak inducer of apoptosis (TWEAK) have been implicated in the pathogenesis of LN and are thus potential biomarkers for disease activity monitoring. Methods: In this study urinary MCP-1 (uMCP-1) and TWEAK (uTWEAK), together with standard markers of disease activity, were analysed in a cohort of 50 biopsy-proven LN patients at baseline, after sixmonths of induction therapy, and at one-year. Results: Throughout the study there was correlation between uMCP-1 and uTWEAK (r=0.52, p< 0.001). Both biomarkers also correlated with standard of care tests and clinical scores. The median [interquartile range] of uMCP-1 and uTWEAK were significantly increased in the active group when compared to the quiescent group (1440 [683–2729] vs 256 [175–477] pg/mL, p< 0.0001, and 209 [117–312] vs 74 [11– 173] pg/mL, p=0.0008, respectively). After completion of induction therapy in the active group, there was no significant difference in biomarker results between the groups. The sensitivity and specificity for indicating disease activity was 95% and 73% for uMCP-1 (area under curve [AUC]=0.875), and 60% and 90% for uTWEAK (AUC=0.783), respectively. Conclusion: uMCP-1 and uTWEAK reflect LN disease activity, and correlate with standard of care biomarkers in a South African cohort. Further studies are needed to assess additional clinical benefit. 2021-09-15T09:37:36Z 2021-09-15T09:37:36Z 2020 2021-09-15T09:06:10Z Master Thesis Masters MMed http://hdl.handle.net/11427/33899 eng application/pdf Division of Chemical Pathology Faculty of Health Sciences
spellingShingle Chemical Pathology
Nephrology
Rusch, Jody Alan
Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
thesis_degree_str Master's
title Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
title_full Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
title_fullStr Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
title_full_unstemmed Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
title_short Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
title_sort using urinary mcp 1 and tweak to assess disease activity in a cohort of south african patients with lupus nephritis
topic Chemical Pathology
Nephrology
url http://hdl.handle.net/11427/33899
work_keys_str_mv AT ruschjodyalan usingurinarymcp1andtweaktoassessdiseaseactivityinacohortofsouthafricanpatientswithlupusnephritis